M&A Deal Summary |
|
|---|---|
| Date | 2025-05-06 |
| Target | Mahana Therapeutics - IBS Assets |
| Sector | Medical Products |
| Buyer(s) | Nerva |
| Sellers(s) | Mahana Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
Nerva is a digital therapeutic for IBS, offering access to evidence-based brain-gut behavioral therapy via mobile phone app. Referred by over 11,000 healthcare practitioners worldwide, the research-backed, six-week program has helped over 300,000 people better manage and live well with their IBS symptoms. Nerva is based in Cremorne, Australia.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2018 |
| Sector | Consumer Services |
Mahana Therapeutics is a developer of digital chronic condition management programs designed to empower patients with chronic conditions to live fuller lives. The company’s first product, Mahana IBS, was the first digital therapeutic to receive FDA clearance for the treatment of IBS and provides cognitive behavioral therapy (CBT) to adults with IBS. Mahana Therapeutics was founded in 2018 and is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-12 |
Cara Care
Berlin, Germany Cara Care is a digital therapeutic app for digestive diseases, which spans medication management as well as dietary and mental health interventions to improve gastrointestinal health. |
Buy | - |
